Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02139111 · ClinicalTrials.gov registry record · Phase 3
PRC-063 in Adolescent ADHD
A Phase 3 study of ADHD, sponsored by Rhodes Pharmaceuticals, L.P..
- Completed
- Registry status
- Phase 3
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT02139111 is a Phase 3 study of ADHD that has completed, run by Rhodes Pharmaceuticals, L.P.. The registered enrollment target is 360 participants, above the 185-participant average among 75 other ADHD trials with a reported enrollment target (95% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT02139111, a Phase 3 study of ADHD, has completed, sponsored by Rhodes Pharmaceuticals, L.P..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this randomized, placebo-controlled, double-blind, parallel group study is to evaluate the clinical efficacy and safety of PRC-063 in adolescents with ADHD.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PRC-063 25 mg
- DRUG PRC-063 45 mg
- DRUG PRC-063 70 mg
- DRUG PRC-063 85 mg
Study Locations (20)
Florida
- Florida Clinical Research Center - Bradenton
- Sarkis Clinical Research - Gainesville
- Sarkis Clinical Trials - Gainesville
- CNS Healthcare Jacksonville - Jacksonville
- Florida Clinical Research Center - Maitlin
- Clinical Neuroscience Solutions - Orlando
- Miami Research Associates - South Miami
- Stedman Clinical Trials - Tampa
California
- UCLA - Los Angeles
- Synergy Clinical Research - National City
- Newport Beach Clinical Research Associates, Inc. - Newport Beach
- Orange County Neuro Phychiatry Research Centre - Orange
North Carolina
- Duke University Medical Center - Durham
- Wake Research Associates - Raleigh
Idaho
- Advanced Clinical Research - Boise
Maryland
- Kennedy Krieger Institute - Baltimore
Nevada
- Center for Psychiatry and Behavioral Medicine Inc. - Las Vegas
Ohio
- University of Cincinnati - Cincinnati
Oklahoma
- IPS Research Company - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02139111
The ClinicalTrials.gov registry entry for NCT02139111 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 185-participant average among 75 other ADHD trials with a reported enrollment target (95% higher). The listed sponsor is Rhodes Pharmaceuticals, L.P., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT02139111 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02139111 about?
NCT02139111 is a clinical study titled "PRC-063 in Adolescent ADHD". The purpose of this randomized, placebo-controlled, double-blind, parallel group study is to evaluate the clinical efficacy and safety of PRC-063 in adolescents with ADHD.
What is the current status of trial NCT02139111?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2014-04. Estimated completion is 2015-05.
What conditions does trial NCT02139111 study?
This clinical trial studies the following conditions: ADHD.
What interventions are being tested in trial NCT02139111?
The interventions under investigation include: Placebo (DRUG), PRC-063 25 mg (DRUG), PRC-063 45 mg (DRUG), PRC-063 70 mg (DRUG), PRC-063 85 mg (DRUG).
Who is sponsoring clinical trial NCT02139111?
This trial is sponsored by Rhodes Pharmaceuticals, L.P., which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02139111 being conducted?
This trial has 20 study locations across California, Florida, Idaho, Maryland, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ADHD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
RECRUITING · Phase 3
-
Treating Parents with ADHD and Their Young Children Via Telehealth: a Hybrid Type I Effectiveness-Implementation Trial
ACTIVE NOT RECRUITING · Phase 3
-
Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
-
Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD
COMPLETED · Phase 3
-
Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD
COMPLETED · Phase 3
-
PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.